Friends of Cancer Research is our country's leading voice in advocating for policies and solutions that will get treatments to patients in the safest and quickest way posible.
Friends of Cancer Research's 2012 Annual Report is now available for download.
Since President Obama signed the Breakthrough Therapy designation into law as part of the Food and Drug Administration Safety and Innovation Act, there have already been nine designations announced.
The Blueprint for Medical Research being drawn-out at the U.S. Senate during the Friends of Cancer Research and Faster Cures briefing.
Senator John McCain was the recipient of our 2012 Lifetime Cancer Leadership Award.
ABT-450* - (AbbVie)
interferon-free 3-DAA treatment of Hepatitis
SD101 – (Scioderm)
topical cream for the treatment of inherited Epidermolysis Bullosa (EB)
Daratumumab – (Janssen)
for the treatment of patients with multiple myeloma
FRIENDS OF CANCER RESEARCH1800 M Street NW Suite 1050 | Washington, DC 20036202.944.6700